NSGO-CTU

NSGO-CTU/HERO

Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study

Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

GCIG SB-001/NSGO-CTU-PEACE

Studying the feasibility of collecting data on patient/carer satisfaction with end of life (EOL) care and of collecting details of that care in women with advanced gynaecological malignancies.

Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-OV24 / NSGO-AVANOVA2

Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. 

Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-OV24 / NSGO-AVANOVA1

Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. 

Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number

ENGOT-EN2 / DGCG

A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.

Contact Person
Status
Disease Site
Lead Cooperative Group
Participating Groups
GCIG Number